What Are the Treatment Options for T790M-Positive Patients?
For patients with T790M-positive NSCLC, third-generation EGFR TKIs like osimertinib have shown significant efficacy. These drugs are designed to selectively inhibit both the activating EGFR mutations and the T790M resistance mutation, while sparing the wild-type EGFR, thus reducing toxicity. Clinical trials and real-world studies have demonstrated improved progression-free survival and overall survival with osimertinib in T790M-positive patients.
